April 28, 2026 | Scientists achieve world first by loading a complete genome onto a quantum computer; Cepheid and Oxford Nanopore announce an expansion of their partnership; Biognosys Group and The Michael J. Fox Foundation for Parkinson’s Research announce a collaboration; and more.
Merck and Google Cloud announced a partnership to enhance Merck's digital backbone as an AI-enabled enterprise. This multi-year investment, valued at up to $1 billion, will deploy an agentic platform across Merck's R&D manufacturing, commercial, and corporate functions—and includes Google Cloud engineers working alongside Merck teams to implement Google Cloud's most sophisticated AI, including Gemini Enterprise. Through this partnership, Merck will build advanced AI solutions on Google Cloud technology to drive new levels of scientific innovation and operational impact. Press release.
Ovation.io and PrecisionLife have reached an agreement to commercialize the outputs of PrecisionLife’s analysis of Ovation’s high quality GLP-1 receptor agonist dataset. The companies have identified novel quantitative markers for strong glycemic control (HbA1c) that are specific and different to those for weight loss (BMI) in a real-world population. PrecisionLife will reproduce, refine, and validate these findings in additional datasets provided by Ovation.io, including studies to confirm predictive performance for leading GLP-1 therapies, such as semaglutide and tirzepatide, against real-world patient outcomes across independent cohorts over the next six months. Press release.
Scientists have achieved a world first by loading a complete genome onto a quantum computer. The breakthrough comes from a collaboration between the Wellcome Sanger Institute and the Universities of Oxford, Cambridge, and Melbourne, with Kyiv Academic University. The genome was loaded onto an IBM quantum computer, powered by the company’s latest 156-qubit Heron processor. The team successfully completed the milestone as part of the Quantum for Bio (Q4Bio) Challenge, a competitive and international research program funded by Wellcome Leap. The challenge aims to accelerate the applications of quantum computing in human health, which may pave the way for faster tracking of infectious disease, deepen understanding of genetic disorders, and more accurately identify disease-causing mutations. Press release.
Cepheid and Oxford Nanopore Technologies announced an expansion of their partnership to develop a workflow for rapid bacterial and fungal pathogen identification. The companies are advancing to the next phase of development, building on a promising beta solution already in use by researchers. In this next phase, the updated workflow will enable pathogen identification, antimicrobial resistance profiling, and genomic antibiotic susceptibility testing predictions for bloodstream infection and sepsis research. Press release.
Discovery Life Sciences and Mindpeak entered a partnership designed to address one of the most stubborn challenges in clinical trial development: inconsistent biomarker interpretation across pathologists. It contributes to variability in patient stratification and eroding confidence in critical go/no-go decisions. The companies will team up by integrating AI-enabled digital image analysis into pathology services for immunohistochemistry and multiplex immunofluorescence in global clinical trials. The collaboration aims to support biopharma R&D and clinical research by improving biomarker quantification and inter-reader concordance, which will help reduce variability, de-risk biomarker-driven trials, and strengthen confidence in critical development decisions. Press release.
Biognosys Group and The Michael J. Fox Foundation for Parkinson’s Research (MJFF) have announced a collaboration to develop sensitive and quantitative biomarker assays for Parkinson’s disease. The partnership supports MJFF’s LRRK2 Investigative Therapeutics Exchange (LITE), a global initiative designed to accelerate the development of therapies and biomarkers targeting leucine-rich repeat kinase 2 (LRRK2). LRRK2 is the most common genetic risk factor for late-onset Parkinson’s disease. Press release.
bioMérieux announced the launch of BIOFIRE SPOTFIRE for pharmaceutical industries. BIOFIRE SPOTFIRE introduces a simple approach to mycoplasma detection, helping biopharmaceutical manufacturers strengthen quality control, accelerate decision-making, and protect patients. The BIOFIRE SPOTFIRE platform is designed to improve operational efficiency and safeguards manufacturing processes. Its automated workflows, intuitive touchscreen interface, and integrated barcode scanning are meant to minimize manual steps, reduce human error, and help ensure secure, traceable data. Press release.
The Bruker Microbiology & Infection Diagnostics division (Bruker Corporation) announced the European launch of MyGenius PRO. Designed for infectious disease diagnostics, the new S2A system enables higher throughput, continuous loading of samples, consumables, and reagents, and supports random-access operation. Like the successful medium-throughput BeGenius system, which excels at assay and sample matrix flexibility, the new higher-throughput MyGenius PRO automates the entire workflow, from patient sample to diagnostic result, enhancing laboratory efficiency and supporting higher-throughput volume testing needs. Press release.
Becton, Dickinson and Company launched the HemoSphere Stream Module. The module delivers real-time, beat-to-beat arterial waveform data from a noninvasive finger cuff directly to compatible multiparameter patient monitors, helping clinicians close gaps between intermittent readings. The compact HemoSphere Stream Module mounts easily to an IV pole. When used with the VitaWave Plus Finger Cuff, the HemoSphere Stream Module serves as the interface that delivers continuous, noninvasive arterial blood pressure waveform data to compatible multiparameter monitors. Press release.
Primerdesign (part of the Novacyt Group) and Origin Sciences announced a strategic partnership to create a new protocol that optimizes DNA extraction from novel rectal mucosal samples. The custom workflow will help to unlock molecular insights from these challenging sample types and improve diagnostic utility in gut health conditions. Origin's OriCol enables reliable, rapid, minimally invasive sample collection of rectal mucus, addressing the urgent need for accurate, affordable in vitro diagnostics for colorectal cancers and advanced adenomas. Primerdesign offers capabilities in custom assay development and high-quality nucleic acid extraction solutions as part of its exsig Mag range. Together, they develop an innovative, robust, and reproducible sample collection and nucleic acid extraction workflow that demonstrates consistent performance and high DNA yields from rectal mucus samples. Press release.